The estimated Net Worth of Mason P Slaine is at least $58.1 Million dollars as of 14 November 2022. Mason Slaine owns over 250,000 units of Certara stock worth over $7,250,336 and over the last 3 years Mason sold CERT stock worth over $50,850,993.
Mason has made over 9 trades of the Certara stock since 2021, according to the Form 4 filled with the SEC. Most recently Mason sold 250,000 units of CERT stock worth $3,890,000 on 14 November 2022.
The largest trade Mason's ever made was selling 620,668 units of Certara stock on 13 September 2021 worth over $18,495,906. On average, Mason trades about 189,027 units every 39 days since 2021. As of 14 November 2022 Mason still owns at least 660,322 units of Certara stock.
You can see the complete history of Mason Slaine stock trades at the bottom of the page.
Mason's mailing address filed with the SEC is C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON, NJ, 08540.
Over the last 5 years, insiders at Certara have traded over $2,048,278,243 worth of Certara stock and bought 97,245 units worth $1,908,085 . The most active insiders traders include Avatar Parent L.P.Eqt Avata..., James E Iii Cashman und Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of $7,828,136. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth $578,319.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: